Natural cough-cold solutions doing well in what is fast becoming a strong season
SALT LAKE CITY — Zarbee’s on Tuesday noted that more consumers have gravitated toward natural solutions over allopathic medicines, at least through the end of December, citing Nielsen scan data.
For the 12 weeks ended Dec. 31, supplemental immune system boosters and homeopathic cough and cold medicines were up 13%, Zarbee’s reported. The trend is even more pronounced across children’s remedies with allopathic medicines declining 15% in the 12 week period while sales of pediatric natural solutions were up 19%, and now make up more than 20% of the category.
FOR MORE COVERAGE OF THE FLU EPIDEMIC CLICK HERE
SoloHealth launches new pay-for-performance ad format
ATLANTA — SoloHealth on Monday announced its new pay-per-performance ad format called SoloTrigger. A permission-based advertising format, SoloTrigger delivers targeted and relevant sponsor content that allows consumers to actively request additional information regarding products or services that will help them live a healthier lifestyle, the company stated.
“Targeted and contextually relevant content is what today’s savvy consumers expect, and brands must meet those expectations to build engaged interactions that drive change in behavior,” stated Dan Bonert, VP advertising sales for SoloHealth. “Our national platform allows brands to become solutions for consumers, providing a meaningful experience with their content and an opportunity to reach health-conscious shoppers when they are engaged and interested in products that are aisles away, not miles away.”
The new ad format is served as consumers are interacting with the SoloHealth Station, an FDA-approved digital health-and-wellness kiosk, while their health and wellness is top of mind and the sponsor content is contextually relevant and targeted.
During a limited three-day trial, close to 11,000 of the 69,000 consumers that interacted with the SoloHealth Station kiosk requested additional product/service information via the new SoloTrigger ad format, representing 16% of the total audience. Based on these initial trials, an execution across SoloHealth’s nationwide footprint would yield results of more than a half a million engaged consumers actively seeking more information on products and/or services during the course of only 30 days. Sponsors only pay when consumers actively engage with the ad content.
The stations are currently located in more than 1,200 retail locations nationwide, including Sam’s Club and Walmart stores, expanding to more than 2,500 store locations by mid-2013 and 4,000 by 2014.
The SoloTrigger ad format is served through one of the SoloHealth Station’s testing paths/sessions — for example, during the BMI, blood pressure or vision screening sessions. Sponsors will have exclusivity during a set time period across the SoloHealth nationwide footprint.
Reuters: CVS/pharmacy will stock Tylenol in only half of its stores
NEW YORK — CVS/pharmacy has decided to stock Tylenol pain reliever in only half of its stores, according to a Reuters report published Monday.
According to the report, CVS will stock Tylenol in each market, but not in each store as CVS seeks to plug any out-of-stock holes left behind by the initial recall of Tylenol three years ago and the brand’s slow trek back to shelf.
Children’s Tylenol liquid suspension had been making a comeback in the past year. According to SymphonyIRI Group data for the 52 weeks ended Oct. 7, across all channels Children’s Tylenol was again the leading internal analgesic brand with $42.5 million in sales, up 27.5%. Across adult tablets, however, Tylenol is the No. 4 brand ranked behind Advil, Aleve and Bayer with a sales decline of 39.2% to $153.9 million. Private brand acetaminophen has been the big winner since Tylenol’s first recalls — sales of all private label internal analgesics totaled $1.3 billion for the 52 weeks ended Oct. 7, up 12.7%.
Perrigo had been preparing for Tylenol to reclaim its marketshare throughout 2013. "We feel the right way for us to look at [Johnson & Johnson] is we’ll take it a quarter by a quarter relative to their return to the marketplace," Perrigo chairman, CEO and president Joe Papa told analysts this past fall. "The operating assumption that we have in our business, it is continue to expect that as they return to the business that instead of our normal 90%, 91% retention rate, when the consumer makes a decision to move from national brand to store brand, … that we would retain approximately 50% of the consumers that have moved from the national brand to the store brand because they could not, there was no access to a national brand product."
"We’re looking forward to the return of the OTC products, and we know that we’re delayed in that return," J&J VP finance and CFO told analysts in October 2012. "We want to do this right. But of course we see those returning over the near term horizon in 2013. And so all in all I think the business is on sound footing. … I think the investments we made were the appropriate ones. They’re paying off," he said. "So I feel pretty good about where the business is right now."
Johnson & Johnson will be addressing analysts on Jan. 22 at 8:30 a.m. EST to discuss the company’s fiscal 2013 results.
Find us on Facebook for more information on drug store news, insights and products.